This move by Trivitron Healthcare to raise additional funds comes hardly with a year after it got commitments of $75 million anchored by Fidelity Growth Partners India. Trivitron, prior to Fidelity, had raised funds from ePlanet Ventures and Headland Capital, who partially exited during the last round.
Trivitron, which posted revenues of Rs 600 crore for the last fiscal, has been expanding rapidly in various geographies and has drawn out a blue-print to have a strong presence in the imaging and lab diagnostics segments through organic growth as well as through acquisition of companies and technologies in Europe and the United States. The management of Trivitron said that their Board of Directors is not considering fresh fund raise as of now.
In addition to expanding its presence at global locations, the fresh inflow of funds will also be used to an extent for the Trivitron Medical Technology Park, a 25-acre manufacturing facility in Chennai and which is mapped to house over 15 different medical technology manufacturing facilities of Trivitron’s subsidiaries and joint ventures.
Trivitron’s joint ventures with Hitachi-Aloka (Japan) for manufacturing ultrasound equipment and with Biosystems (Spain) for lab diagnostics reagents are already operational. The company has recently set up centres of innovation for biomedical equipment in collaboration with the Indian Institute of Technology (IIT), Madras and under the leadership of its Director (R&D), Prof. Bhuvaneshwar, a well recognized innovator in this area.
Trivitron was founded in 1997 by Dr G S K Velu after his stint as the Country Head for Chiron Diagnostics, before embarking on an entrepreneurial journey. In addition to Trivitron, Dr Velu has co-founded and built a pan-India path lab chain, Metropolis Healthcare, as well as Medfort, a chain of single specialty, eye-care and diabetes-care hospitals.
He has also co-founded a joint venture with the Apollo Hospitals Group for dental clinics(Apollo White) and dialysis centres (Apollo Dialysis).
This move by Trivitron to raise fresh funds comes at a time when many more private equity fund are looking to invest in the entire value of healthcare chain. The healthcare and life sciences sector witnessed a 66% growth in the value of investments, seeing an increase from $130 million in Q1 of 2013 to $215 million in Q2 of 2013, according to data from PwC.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)